Effects of heparin on liver fibrosis in patients with chronic hepatitis B

World Journal of Gastroenterology

Volumn 9, Issue 7, 2003, Pages 1611-1614

  Shi, Jun ^a   Hao, Jing Hua ^a   Ren, Wan Hua ^a   Zhu, Ju Ren ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; COLLAGEN TYPE 4; DIAMMONIUM GLYCYRRHIZINATE; FLUX; GLUCOSE INSULIN POTASSIUM; HEPARIN; HYALURONIC ACID; LOW MOLECULAR WEIGHT HEPARIN; POTASSIUM MAGNESIUM ASPARTATE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL;

EID: 0043066540     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i7.1611     Document Type: Article

References (33)

1. Yuan TX, Zhang JS, Zhang YE, Chen Q. Culture of rat liver Ito cells and the observation of inhibitory effect of heparin on Ito cells. Shanghai Yike Daxue Xuebao 1996; 23: 90-93
2. Bissell DM, Friedman SL, Maher JJ, Roll FJ. Connective tissue biology and hepatic fibrosis: Report of a conference. Hepatology 1990; 11: 488-498
3. Schuppan D. Structure of the extracellular matrix in normal and fibrotic liver: Collagens and glycoproteins. Semin Liver Dis 1990; 10: 1-10
4. Friedman SL. Cellular source of collagen and regulation of collagen production in liver. Semin Liver Dis 1990; 10: 20-29
5. Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 2001; 21: 437-451
6. Dai WJ, Jiang HC. Advances in gene therapy of liver cirrhosis, a review. World J Gastroenterol 2001; 7: 1-8
7. Kinnman N, Goria O, Wendum D, Gendron MC, Rey C, Poupon R, Housset C. Hepatic stellate cell proliferation is an early platelet-derived growth faactor-mediated cellular event in rat cholestatic liver injury. Lab Invest 2001; 81: 1709-1716
8. Gandhi CR, Kuddus RH, Uemura T, Rao AS. Endothelin stimulates transforming growth factor-β1 and collagen synthesis in stellate cells from control but not cirrhotic rat liver. Eur J Pharmacol 2000; 406: 311-318
9. Gabriel A, Kuddus RH, Rao AS, Gandhi CR. Down-regulation of endothelin receptor by transforming growth factorβ1 in hepatic stellate cells. Hepatol 1999; 30: 440-450
10. Huang GC, Zhang JS, Zhang YE. Effects of retinoic acid on proliferation, phenotype and expression of cyclin-dependent kinase inhibitors in TGF-β1 stimulated rat hepatic stellate cells. World J Gastroenterol 2000; 6: 819-823
11. Chen PS, Zhai WR, Zhou XM, Zhang JS, Zhang YE, Ling YQ, Gu YH. Effects of hypoxia, hyperoxia on the regulation of expression and activity of matrix metalloproteinase-2 in hepatic stellate cells. World J Gastroenterol 2001; 7: 647-651
12. Wang JY, Zhang QS, Guo JS, Hu MY. Effects of glycyrrhetinic acid on collagen metabolism of hepatic stellate cells at different stages of liver fibrosis in rats. World J Gastroenterol 2001; 7: 115-119
13. Eng FJ, Friedman SL, Fibrogenesis I. New insight into hepatic stellate cell activation: The simple becomes complex. Am J Physiol 2000; 279: G7-G11
14. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-2250
15. Albanis E, Friedman SL. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis 2001; 5: 315-334
16. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, Conti M, Huet S, Ba N, Buffet C, Bedossa P. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34: 738-744
17. Schneiderhan W, Schmid-Kotsas A, Zhao J, Grunert A, Nussler A, Weidenbach H, Menke A, Schmid RM, Adler G, Bachem MG. Oxidized low-density lipoproteins bind to the scavenger receptor, CD36, of hepatic stellate cells and stimulate extracellular matrix synthesis. Hepatology 2001; 34: 729-737
18. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001; 21: 373-384
19. Vaillant B, Chiaramonte MG, Cheever AW, Soloway PD, Wynn TA. Regulation of hepatic fibrosis and extracellular matrix genes by the Th response: New insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol 2001; 167: 7017-7026
20. Breitkopf K, Lahme B, Tag CG, Gressner AM. Expression and matrix deposition of latent transforming growth factor beta binding proteins in normal and fibrotic rat liver and transdifferentiating hepatic stellate cells in culture. Hepatology 2001; 33: 387-396
21. Bruck R, Genina O, Aeed H, Alexiev R, Nagler A, Avni Y, Pines M. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 2001; 33: 379-386
22. Watanabe T, Niioka M, Hozawa S, Kameyama K, Hayashi T, Aira M, Ishikawa A, Maruyama K, Okazaki I. Gene expression of interstitial collagenase in both progressive and recovery phase of rat liver fibrosis induced by carbon tetrachloride. J Hepatol 2000; 33: 224-235
23. Nakamura T, Sakata R, Ueno T, Sata M, Ueno H. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 2000; 32: 247-255
24. Castera L, Hartmann DJ, Chapel F, Guettier C, Mall F, Lons T, Richardet JP, Grimbert S, Morassi O, Beaugrand M, Trinchet JC. Serum laminin and type IV collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis. J Hepatol 2000; 32: 412-418
25. Brenner DA, Waterboer T, Choi SK, Lindquist JN, Stefanovic B, Burchardt E, Yamauchi M, Gillan A, Rippe RA. New aspects of hepatic fibrosis. J Hepatol 2000; 32(Suppl 1): 32-38
26. Benyon RC, Iredale JP. Is liver fibrosis reversible? Gut 2000; 46: 443-446
27. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-2250
28. Kopke-Aguiar LA, Martins JR, Passerotti CC, Toledo CF, Nader HB, Borges DR. Serum hyaluronic acid as a comprehensive marker to assess severity of liver disease in schistosomiasis. Acta Trop 2002; 84: 117-126
29. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertention. Hepatology 1995; 21: 1238-1247
30. Hao JH, Shi J, Ren WH, Han GQ, Wang WZ, Zhu JR, Wang SY, Xie YB. Usage of heparin in the patients with chronic hepatitis B. Wei Xunhuan Xue Zazhi 2001; 11: 9-11
31. Matsumoto S, Yamamoto K, Nagano T, Okamoto R, Ibuki N, Tagashira M, Tsuji T. Immunohistochemical study on phenotypical changes of hepatocytes in liver disease with reference to extracellular matrix composition. Liver 1999; 19: 32-38
32. Marcato PS, Bettini G, Della Salda L, Galeotti M. Pretelangiectasis and telangiectasis of the bovine liver: A morphological immunohistochemical and ultrastructural study. J Comp Pathol 1998; 119: 95-100
33. Khosla S, Kunjummen B, Guerrero M, Manda R, Razminia M, Trivedi A, Vidyarthi V, Elbazour M, Ahmed A, Lubell D. Safety and efficacy of combined use of low molecular weight heparin (enoxaparin, lovenox) and glycoprotein IIb/IIIa receptor antagonist (eptifibatide, integrelin) during nonemergent coronary and peripheral vascular intervention. Am J Ther 2002; 9: 488-491